利伐沙班治疗对脑卒中患者血清炎性因子、MMP-9和NT-proBNP水平的影响  

Effects of rivaroxaban on serum levels of inflammatory factors,MMP-9,and NT-proBNP in patients with stroke

作　　者：李翠 腾国良 刘锋昌 LI Cui;TENG Guo-liang;LIU Feng-chang(Department of Neurology Ⅰ,the North Hospital of Xi'an City,Xi'an 710043,Shaanxi,CHINA;Department of Neurology Ⅲ,the North Hospital of Xi'an City,Xi'an 710043,Shaanxi,CHINA)

机构地区：[1]西安市北方医院神经一科,陕西西安710043 [2]西安市北方医院神经三科,陕西西安710043

出　　处：《海南医学》2022年第3期295-298,共4页Hainan Medical Journal

摘　　要：目的探讨利伐沙班治疗对脑卒中患者血清炎性因子、基质金属蛋白酶-9(MMP-9)、脑钠肽前体N-末端肽(NT-proBNP)水平的影响。方法选取2019年6月至2020年8月西安市北方医院收治的72例给予口服利伐沙班片治疗的急性脑卒中患者作为观察组,按照脑损伤不同程度分为轻度脑损伤组34例,中度脑损伤组25例,重度脑损伤组13例。另选取在我院体检中心体检的健康者60例作为对照组。比较观察组患者治疗前与对照组受检者的血清白细胞介素-6(IL-6)、基质金属蛋白酶-9(MMP-9)、脑钠肽前体N-末端肽(NT-proBNP)水平;比较观察组患者治疗前与治疗后1周、2周、3周的血清白细胞介素-6(IL-6)、基质金属蛋白酶-9(MMP-9)、脑钠肽前体N-末端肽(NT-proBNP)水平;比较观察组患者治疗前与治疗后1周、3周的中风风险评估系统(CHADS2)评分、日常生活活动能力表(Barthel)评分、神经功能缺损程度(SSS)评分情况。结果观察组患者治疗前的血清IL-6、MMP-9、NT-proBNP水平明显高于对照组,差异均有统计学意义(P<0.05);重度脑损伤组患者的血清IL-6、MMP-9、NT-proBNP水平明显高于轻、中度脑损伤组患者,差异均有统计学意义(P<0.05);观察组患者治疗后的血清IL-6、MMP-9、NT-proBNP水平明显低于治疗前,CHADS2、SSS评分明显低于治疗前,但Barthel评分明显高于治疗前,差异均有统计学意义(P<0.05)。结论利伐沙班治疗脑卒中疗效明显,其能有效降低脑卒中血清中IL-6、MMP-9、NT-proBNP水平,能有效改善神经损害程度。Objective To investigate the effect of rivaroxaban treatment on serum levels of inflammatory factors,matrix metalloproteinase-9(MMP-9),N-terminal pro-brain natriuretic peptide(NT-proBNP)in patients with stroke.Methods From June 2019 to August 2020,72 patients with acute stroke who were treated with oral rivaroxaban tablets were selected as the observation group.According to the degree of brain injury,the patients were divided into mild brain injury(n=34),moderate brain injury(n=25),severe brain injury(n=13).Sixty healthy people who were examined in the physical examination center of the hospital were selected as the control group.The serum levels of interleukin-6(IL-6),MMP-9,and NT-proBNP were compared between the observation group and the control group before treatment;IL-6,MMP-9,NT-proBNP levels in the observation group were compared before treatment and one week,two weeks,three weeks after treatment;stroke risk assessment system(CHADS2)score,the activity of daily living(Barthel)score,and the degree of neurological impairment(SSS)scores of the patients were compared before treatment and 1 week and 3 weeks after treatment.Results The serum IL-6,MMP-9,and NT-proBNP levels of the observation group before treatment were significantly higher than those of the control group(P<0.05).The serum IL-6,MMP-9,NT-proBNP levels in the severe brain injury group were significantly higher than those in the mild and moderate brain injury group(P<0.05).In the observation group,the serum levels of IL-6,MMP-9,and NT-proBNP after treatment were significantly lower than those before treatment,CHADS2 score and SSS score were significantly lower than those before treatment,but Barthel score was significantly higher than that before treatment,all with statistically significant difference(P<0.05).Conclusion Rivaroxaban is effective in treating stroke.It can effectively reduce the levels of IL-6,MMP-9,and NT-proBNP in the serum of stroke,and greatly improve the degree of nerve damage.

关 键 词：利伐沙班 脑卒中 白介素-6 基质金属蛋白酶-9 脑钠肽前体N-末端肽 

分 类 号：R743.3[医药卫生—神经病学与精神病学]